The use of sugammadex in a patient with Kennedy′s disease under general anesthesia

Takeuchi, Risa; Hoshijima, Hiroshi; Doi, Kouki; Nagasaka, Hiroshi

doi:10.4103/1658-354x.136640

Cited by 8 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the use of sugammadex in other lower motor neuron disease has been reported. Takeuchi et al [ 15 ] used 40 mg of rocuronium for intubation, and 2 mg/kg of sugammadex was used for reversal of neuromuscular blockade without any complications in a patient with spinal and bulbar muscular atrophy which is X-linked recessive lower motor neuron disease. However, no reports have described the use of sugammadex in patients with PMA with bulbar symptoms.…”

Section: Discussionmentioning

confidence: 99%

Use of sugammadex in a patient with progressive muscular atrophy and in a patient with amyotrophic lateral sclerosis

Yoo¹,

Kim²,

Park³

et al. 2017

Medicine

View full text Add to dashboard Cite

Introduction:We herein present 2 cases involving the combination of rocuronium and sugammadex in patients with motor neuron disease. The patients were a 54-year-old man with progressive muscular atrophy who underwent removal of internal fixators in the arm and leg, and a 66-year-old woman with amyotrophic lateral sclerosis who underwent skin grafting in the left lower leg. General anesthesia was induced with propofol, rocuronium, and remifentanil and maintained with desflurane and remifentanil. At the end of the surgical procedure, we administered sugammadex. Three or 4 minutes after administration of sugammadex, the patients began to breathe spontaneously and were extubated without complications.Conclusion:Sugammadex can be used successfully to reverse neuromuscular blockade in patients with motor neuron disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of sugammadex in a patient with progressive muscular atrophy and in a patient with amyotrophic lateral sclerosis

Yoo¹,

Kim²,

Park³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…Given that SMBA is a motor neuron disease with bulbar dysfunction, many anesthesiologists may be concerned about the use of neuromuscular blocking drugs and their reversal agents. Interestingly, however, there have been no reported complications following the use of these agents so far [ 7 , 11 ]. In this case, neither rocuronium nor sugammadex, used during the first and second instances of general anesthesia, was associated with any complications when the patient was 67 and 68 years old.…”

Section: Discussionmentioning

confidence: 99%

Previously Undiagnosed Spinal and Bulbar Muscular Atrophy as a Cause of Airway Obstruction after Robot-Assisted Laparoscopic Prostatectomy

Niki

Tachikawa

Sano

et al. 2017

Case Reports in Anesthesiology

View full text Add to dashboard Cite

Background Preoperative vocal cord paralysis is a risk factor for postoperative respiratory distress following extubation after general anesthesia. We present an unusual case where a geriatric patient developed airway obstruction after robot-assisted laparoscopic prostatectomy. Case Presentation A 67-year-old male, who had suffered from left vocal cord paralysis of unknown etiology, was scheduled for robot-assisted laparoscopic prostatectomy (RALP). General anesthesia was performed without any problems. The patient, however, developed airway obstruction one hour after extubation and was reintubated following commencement of mechanical ventilation for one day. At the age of 70 years, the patient received an emergency tracheostomy due to bilateral vocal cord paralysis and then was diagnosed with spinal and bulbar muscular atrophy (SBMA). Although no muscle weakness of either upper or lower extremities was observed, rocuronium showed hypersensitivity during total laryngectomy under general anesthesia. Conclusions Vocal cord paralysis combined with postoperative laryngeal edema, the cause of which was presumed to be SBMA, likely caused airway obstruction after RALP. As neuromuscular symptoms progress gradually in patients with SBMA, muscle relaxants should be used carefully, even if patients with SBMA present no immobility of their extremities.

show abstract

Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade

Schaller

Lewald

2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

After approval in Europe in 2008 and Asia in 2010, sugammadex has recently been approved in the USA and Canada. This will open the field for further research especially for the use in special patient populations and specific diseases. Due to its pharmacodynamic profile, sugammadex in combination with rocuronium might have the potential to displace succinylcholine as the gold standard muscle relaxant for rapid sequence inductions. The use of rocuronium or vecuronium with the potential to reverse its action with sugammadex seems to be safe in patients with impaired neuromuscular transmission, i.e. (neuro)muscular diseases including myasthenia gravis. Data from long-term use of sugammadex is not yet available. Evidence towards an economic advantage of using sugammadex, justifying the relatively high costs for an anesthesia-related drug, is missing.

show abstract

The use of sugammadex in a patient with Kennedy′s disease under general anesthesia

Cited by 8 publications

References 22 publications

Use of sugammadex in a patient with progressive muscular atrophy and in a patient with amyotrophic lateral sclerosis

Use of sugammadex in a patient with progressive muscular atrophy and in a patient with amyotrophic lateral sclerosis

Previously Undiagnosed Spinal and Bulbar Muscular Atrophy as a Cause of Airway Obstruction after Robot-Assisted Laparoscopic Prostatectomy

Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade

Contact Info

Product

Resources

About